about
Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteersOccupational and environmental exposure to pesticides and cytokine pathways in chronic diseases (Review)Improvement in survival after paraquat ingestion following introduction of a new formulation in Sri LankaSystems Toxicology: Real World Applications and Opportunities.The ethics of human volunteer studies involving experimental exposure to pesticides: unanswered dilemmasInternational STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposesSystems toxicology: from basic research to risk assessment.Escitalopram causes fewer seizures in human overdose than citalopram.The interplay between environmental and genetic factors in Parkinson's disease susceptibility: the evidence for pesticides.Neurodevelopmental and neurobehavioural effects of polybrominated and perfluorinated chemicals: a systematic review of the epidemiological literature using a quality assessment scheme.Bisphenol A--Why an adverse outcome pathway framework needs to be applied.Anthracycline-dependent cardiotoxicity and extracellular matrix remodeling.Effects of 3-monochloropropane-1,2-diol (3-MCPD) and its metabolites on DNA damage and repair under in vitro conditions.A framework for cumulative risk assessment in the 21st century.Problem formulation for risk assessment of combined exposures to chemicals and other stressors in humans.The European Registered Toxicologist (ERT): Current status and prospects for advancement.Changes in the concentrations of creatinine, cystatin C and NGAL in patients with acute paraquat self-poisoning.Retrospective analysis of stimulant abuse cases reported to the Swiss Toxicological Information Centre during 1997-2009.White paper on the promotion of an integrated risk assessment concept in European regulatory frameworks for chemicals.High-dose immunosuppression to prevent death after paraquat self-poisoning - a randomised controlled trial.Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes.Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity.OECD/EFSA workshop on developmental neurotoxicity (DNT): The use of non-animal test methods for regulatory purposes.Effects of resveratrol on carbon monoxide-induced cardiotoxicity in rats.Perspectives for integrating human and environmental risk assessment and synergies with socio-economic analysis.With the benefit of hindsight: trials using retrospective controls versus randomized controlled trials in clinical toxicologyEnvironmental contaminants and target organ toxicities - new insights into old problems.Contact dermatitis due to a new fungicide used in the tulip bulb industryAn assessment of the dietary uptake of di-2-(ethylhexyl) adipate (DEHA) in a limited population studyVehicle effects on in vitro percutaneous absorption through rat and human skinEffect of dosing vehicle on the dermal absorption of fluazifop-butyl and fomesafen in rats in vivoParaquat poisoningIn vitro tape stripping as a model for in vivo skin stripping
P50
Q28345551-0C5A0553-0ECA-4B5A-A386-927D2980CD97Q28389743-2D511BC8-87E4-4BF5-BE1A-F77098BE67F1Q28472237-AFDC98EF-2300-430B-8F5A-204073124133Q33577370-CA044C03-1529-445C-B1CF-75AD5CCD10EEQ34097909-DDE4B3CA-3388-4ED7-AEC3-2CC514E82CB9Q35024730-E3388CC5-7DB8-4F8C-9F6B-9D152CA9BEC6Q37661327-A7C2018C-6E72-4F70-B668-77F86A94CC05Q37695292-C5885042-0B97-40A8-92B8-B23BDF5B4E49Q38072236-9A699633-A552-4CEC-BDC5-A3A28E95F298Q38192359-E02696BC-479E-42D4-A905-3CBD241FB33CQ38212028-6C7E17E6-051C-4F51-A556-323AD2C51D44Q38257378-F0D84E82-C55B-4CBC-8E3C-90B539FB168DQ38805439-B9335919-1537-47EC-BA8B-7A33E1A2E4F7Q39338793-2073414D-C988-4F36-8AD2-ACD4E8F26DFFQ39339057-AEB8FC85-BFC6-4F02-9C9D-C6DA3B6994D6Q40682256-B5E5BEEA-5FD4-49D0-9A49-29A34C4D3F63Q41853403-4A2441F0-E5AB-455C-8128-216032FF8A02Q42770943-2537CFCB-6A06-46FB-8ED3-16085CBB65DBQ46748871-7EE991C8-AFC6-4BCF-B0F1-6762586EA68CQ48369511-F4299C1F-507D-4B7C-A861-1448859481F5Q49971717-02745374-8738-4025-9C03-1B4028E64EB8Q50421707-772B3E2D-4C23-4D35-A619-9FCD5B480075Q50444225-7C96480C-0B44-4EAE-9D15-74B60C444CE8Q51616223-89861D27-8F43-4788-8535-2696136400F7Q51815446-E1883FD6-0C7A-42A0-963E-E9BE7DE17B54Q59624426-73A60B6D-E36F-4F2D-A845-72EE2E992F25Q64937380-5134D85A-A7ED-44AB-BDE4-D13EEF8E1847Q71572481-CF7582D1-1C21-47DC-A913-34C842B9E943Q72302143-B0160315-5FDB-44E2-AB4E-E0F4F50D2654Q72543101-C17168F3-601D-4450-A5C4-9CC0E13E5AFCQ72800295-04647084-1994-40F2-BCA4-A0949C5E02B3Q77937821-F36967BD-882C-46D4-9BA4-8F0374CE6FE9Q84696041-A53E5A97-9E4C-4E18-BA7B-57A4C29FAAB8
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Martin F Wilks
@ast
Martin F Wilks
@en
Martin F Wilks
@es
Martin F Wilks
@nl
type
label
Martin F Wilks
@ast
Martin F Wilks
@en
Martin F Wilks
@es
Martin F Wilks
@nl
prefLabel
Martin F Wilks
@ast
Martin F Wilks
@en
Martin F Wilks
@es
Martin F Wilks
@nl
P106
P31
P496
0000-0003-3984-5935